1. Home
  2. ELVN

ELVN

Enliven Therapeutics Inc.

Logo Enliven Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 12:32pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Founded: 2016 Country:
United States
United States
Employees: N/A City: BOULDER
Market Cap: 808.8M IPO Year: 2020
Target Price: $34.00 AVG Volume (30 days): 234.6K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.01 EPS Growth: N/A
52 Week Low/High: $9.80 - $26.00 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: